Establishment and validation of prediction model for VCZ stable maintenance dose
DISEASE
According to the admission order, the 302 patients were divided into the derivation and validation groups. There were no significant differences in the general clinical data (sex, age, body weight, albumin, co-administered PPIs, co-administered hormones, CYP2C19 phenotype, underlying disease, etc.) between the derivation and validation groups (In the derivation group, the stable maintenance dose was used as the independent variable (Y), and age (xThere was no significant difference between the predicted VCZ maintenance dose and the actual maintenance dose according to the predictive model and the actual maintenance dose (376.10 ± 57.87 vs. 374.00 ± 47.93 mg, The data of 13 patients with different rates (≥ 20%) were compared and analyzed. It was shown that the 